Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces a proposed Placing and Subscription of 3,500,000 New Ordinary Shares at a price of 60 pence to raise £2.1 million (before expenses).
Nexvet has signed a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to provide future clinical-scale biomanufacturing services for Nexvet’s most advanced product candidates, NV-01 and NV-02, being developed for chronic pain management indications in dogs and cats. The contract also allows for Fujifilm to become the commercial manufacturer of these product candidates.
Read more about Nexvet Advances Manufacturing Strategy
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P. aeruginosa bacteriophages after exposure to nebulizer systems applicable for use in future clinical trials will be presented at the European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including osteoarthritis, in cats.
AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana, Slovenia, was cleared by JAZMP, the Agency of the Republic of Slovenia for Medicinal Products and Medical Devices, to manufacture bacteriophages under current Good Manufacturing Practices (cGMP) standards.
Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce that the first patient has been successfully treated in its RAPPER II (“Robot-Assisted PhysiotheraPy Exercises with REX”) clinical trial.
Read more about Rex Bionics – First Patient Treated in RAPPER II Clinical Trial
SeaDragon (NZX.SEA), New Zealand’s largest refiner and blender of high quality, fish oils and fractions, including Omega 3 oils, today reports financial results in line with its March forecasts and continued progress on the development of its new Omega 3 fish oil refinery.
Read more about SeaDragon Full Year Result to 31 March 2015
29 May 2015, Rex Bionics Plc (AIM: RXB) the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces...
Read more about Rex Bionics – Audited Results period ended 31 Mar 2015
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015.
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role at Nexvet in August 2015.